TherapeuticsMD Inc (NASDAQ:TXMD) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 15th total of 79,360,000 shares. Approximately 36.6% of the company’s shares are sold short. Based on an average daily volume of 3,650,000 shares, the short-interest ratio is presently 23.8 days.

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of TherapeuticsMD in a report on Monday, December 23rd. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. Stifel Nicolaus decreased their price target on shares of TherapeuticsMD from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, October 28th. Finally, Noble Financial restated a “buy” rating and issued a $13.00 price objective on shares of TherapeuticsMD in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $9.60.

In other TherapeuticsMD news, Director Brian Bernick purchased 36,000 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was bought at an average price of $2.75 per share, with a total value of $99,000.00. Following the completion of the purchase, the director now directly owns 98,000 shares of the company’s stock, valued at approximately $269,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Group L. P. Column purchased 4,387 shares of the business’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was bought at an average price of $12.66 per share, for a total transaction of $55,539.42. Insiders have acquired a total of 112,387 shares of company stock valued at $352,539 in the last ninety days. 18.91% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC bought a new position in shares of TherapeuticsMD in the 3rd quarter worth about $37,000. Sigma Planning Corp purchased a new stake in TherapeuticsMD in the third quarter worth about $42,000. Moloney Securities Asset Management LLC grew its holdings in TherapeuticsMD by 42.9% in the third quarter. Moloney Securities Asset Management LLC now owns 15,000 shares of the company’s stock worth $54,000 after purchasing an additional 4,500 shares during the period. Tower Research Capital LLC TRC grew its holdings in TherapeuticsMD by 130.8% in the second quarter. Tower Research Capital LLC TRC now owns 15,400 shares of the company’s stock worth $40,000 after purchasing an additional 8,727 shares during the period. Finally, Lido Advisors LLC increased its stake in shares of TherapeuticsMD by 29.0% during the second quarter. Lido Advisors LLC now owns 17,178 shares of the company’s stock valued at $44,000 after purchasing an additional 3,865 shares in the last quarter. 63.57% of the stock is currently owned by hedge funds and other institutional investors.

Shares of TXMD stock opened at $2.45 on Wednesday. The business’s fifty day moving average is $2.39 and its 200 day moving average is $2.80. The company has a quick ratio of 2.69, a current ratio of 2.85 and a debt-to-equity ratio of 24.29. The stock has a market cap of $642.70 million, a price-to-earnings ratio of -4.15 and a beta of 1.66. TherapeuticsMD has a twelve month low of $1.82 and a twelve month high of $6.09.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. The business had revenue of $8.21 million during the quarter, compared to analyst estimates of $8.05 million. TherapeuticsMD had a negative return on equity of 430.28% and a negative net margin of 427.70%. The company’s revenue for the quarter was up 136.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) earnings per share. Equities research analysts expect that TherapeuticsMD will post -0.69 earnings per share for the current fiscal year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: What is the quiet period?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.